Early HIV diagnosis enables prompt treatment initiation, thereby contributing to decreased morbidity, mortality, and transmission. We aimed to describe the association between distance from residence to testing sites and HIV disease stage at diagnosis. Using HIV surveillance data, we identified all new HIV diagnoses made at publicly funded testing sites in central North Carolina during 2005-2013. Early-stage HIV was defined as acute HIV (antibody-negative test with a positive HIV RNA) or recent HIV (normalized optical density <0.8 on the BED assay for non-AIDS cases); remaining diagnoses were considered post-early-stage HIV. Street distance between residence at diagnosis and (1) the closest testing site and (2) the diagnosis site was dichotomized at 5 miles. We fit log-binomial models using generalized estimating equations to estimate prevalence ratios (PR) and robust 95% confidence intervals (CI) for post-early-stage diagnoses by distance. Models were adjusted for race/ethnicity and testing period. Most of the 3028 new diagnoses were black (N = 2144; 70.8%), men who have sex with men (N = 1685; 55.7%), and post-early-stage HIV diagnoses (N = 2010; 66.4%). Overall, 1145 (37.8%) cases traveled <5 miles for a diagnosis. Among cases traveling ≥5 miles for a diagnosis, 1273 (67.6%) lived <5 miles from a different site. Residing ≥5 miles from a testing site was not associated with post-early-stage HIV (adjusted PR, 95% CI: 0.98, 0.92-1.04), but traveling ≥5 miles for a diagnosis was associated with higher post-early HIV prevalence (1.07, 1.02-1.13). Most of the elevated prevalence observed in cases traveling ≥5 miles for a diagnosis occurred among those living <5 miles from a different site (1.09, 1.03-1.16). Modest increases in post-early-stage HIV diagnosis were apparent among persons living near a site, but choosing to travel longer distances to test. Understanding reasons for increased travel distances could improve accessibility and acceptability of HIV services and increase early diagnosis rates.
Introduction
Diagnosis and presentation to care during early stages of HIV contribute to decreased disease-related morbidity, mortality and transmission risk (The Antiretroviral Therapy Cohort Collaboration, 2008; Cohen et al., 2011; Marks, Crepaz, Senterfitt, & Janssen, 2005; Metsch et al., 2008) . However, approximately 25% of newly HIVdiagnosed persons in the United States are simultaneously diagnosed with AIDS, representing diagnoses late in the course of disease (HIV Surveillance Supplemental Report, 2015) .
A lack of accessible HIV services and living in rural areas contribute to testing delays (Leibowitz & Taylor, 2007; Ohl & Perencevich, 2011) . In the American South, many HIV-infected persons live in rural areas , and poverty, distrust in the medical system and perceived stigma toward HIV-infected persons result in additional barriers to HIV services (Konkle-Parker, Erlen, & Dubbert, 2008; Krawczyk, Funkhouser, Kilby, & Vermund, 2006) . Our primary goals were to determine if HIV diagnosis more than approximately six months after infection (post-early-stage) was associated with (1) distance from residence to the closest testing site, (2) distance from residence to the diagnosis site and/or (3) being diagnosed farther away than geographically necessary among those living near a testing site.
newly diagnosed with HIV at publicly funded testing sites who were (1) ≥16 years of age (to protect confidentiality of adolescent cases), (2) not living in correctional facilities and (3) residing within a 52-county study area in central NC. The 48 excluded counties contained <20% of new HIV diagnoses; spatial analyses in areas of very low prevalence are problematic and associated with privacy concerns.
For all new diagnoses reported in eHARS, we assigned a disease stage at diagnosis using a three-step process. First, we identified all acute HIV infection (AHI) as antibody-negative tests with reproducibly positive HIV RNA (Pilcher et al., 2002 (Pilcher et al., , 2004 . Next, we identified cases diagnosed with AIDS ≤6 months after an HIV diagnosis. For the remaining cases, the CDC-administered serologic testing algorithm for recent HIV seroconversion (STARHS) results were used to distinguish recent (≤ approximately six months) from chronic (> approximately six months) infection, based on a normalized optical density cutpoint of <0.8 on the BED assay (Hall et al., 2008) . All non-AHI and non-AIDS cases without STARHS testing results were excluded from analysis. We considered AHI and recent diagnoses as "early-stage" disease and chronic and AIDS diagnoses as "post-early-stage" disease.
Residential addresses of new HIV cases were geocoded to an ESRI-supplied NC street basemap using Arc-GIS (version 10.1, Redlands, CA). Persons with incomplete addresses were geocoded to a populationweighted, random point in the provided zip code. Census tract at diagnosis was assigned based on this geocoded address. The addresses of 326 publicly funded HIV testing sites in NC providing samples to the state lab for processing (Epidemiologic Profile for HIV/STD Prevention and Care Planning 2013; HIV/STD Testing: Programs and Services, 2014) were also geocoded. The street distance (miles) between each case's residential address and both (1) the diagnosis site and (2) the closest publicly funded testing site was calculated using the ArcGIS Network Analyst extension. We dichotomized each distance variable at 5 miles.
We fit log-binomial regression models using generalized estimating equations to estimate prevalence ratios (PR) and robust 95% confidence intervals (CI) of postearly-stage diagnoses by dichotomized distance (<5 miles versus ≥5 miles) between residence and the closest testing site. We repeated this analysis twice, first using distance to diagnosis site as the explanatory variable and then using a composite distance measure (closest site and diagnosis site <5 miles; diagnosed ≥5 miles, but closest testing site <5 miles; closest site and diagnosis site ≥5 miles). The latter analysis evaluated whether the prevalence of post-early-stage diagnosis was associated with being diagnosed somewhere other than the most proximate site among those living <5 miles of a testing site. We accounted for clustering of the outcome at the census tract, which served as a proxy for neighborhood-level characteristics, with an exchangeable correlation matrix. Models were adjusted for race/ethnicity and time period based on a directed acyclic graph. Effect measure modification by race/ethnicity and sexual risk status was also assessed.
All statistical analyses were conducted in SAS version 9.3 (Cary, NC). This research was deemed exempt by the University of North Carolina Institutional Review Board.
Results
Among 4023 persons diagnosed with HIV at publicly funded testing sites in central NC during 2005-2013, we could classify disease stage at diagnosis for 3242 (80.6%) persons. We excluded an additional 214 cases without a geocodable address, resulting in a study population comprised of 3028 people (1018 early-stage; 2010 post-early-stage). Most were black (N = 2144; 70.8%) and men who have sex with men (MSM) (N = 1685; 55.7%, including MSM who also injected drugs). The median age was 29 years (IQR 23-40) ( Table 1) .
Approximately 35% of black and white persons were diagnosed during early-stage disease, compared to 21.5% of Hispanics. Early-stage diagnoses had a lower median age (25 versus 32 years) and were most common from 2011 to 2013 (38.2%). (Table 1) .
All new diagnoses lived within 30 miles and 80% lived <5 miles from a publicly funded testing facility. The median distance traveled for a diagnosis was greater than that to the closest site [6.6 (IQR 3.6-12.3) versus 2.1 miles (IQR 1.1-4.1)]. Overall, 1145 (37.8%) cases were diagnosed <5 miles from their residence ( Table  2) . Of the remaining 1883 cases who traveled ≥5 miles for their diagnosis, 1273 (67.6%) lived <5 miles from a different publicly funded testing site.
Living ≥5 miles from the closest testing site compared to <5 miles had no association with post-early-stage diagnosis (adjusted aPR = 0.97, 95% CI 0.91-1.03). The prevalence of post-early-stage diagnosis among persons traveling ≥5 miles for a diagnosis was slightly greater than those traveling <5 miles (aPR = 1.08, 95% CI 1.02-1.14) ( Table 2) .
The increase in prevalence of post-early-stage diagnoses among cases who traveled ≥5 miles for a diagnosis occurred primarily among persons who lived <5 miles from a different publicly funded testing site (aPR = 1.09, 95% CI 1.03-1.16). This translated to a six-percentage-point absolute difference in post-early-stage disease prevalence compared to those who tested at sites <5 miles from their residence. Upon further stratification, this relationship was statistically significant only among black (aPR = 1.13, 95% CI 1.05-1.21) and MSM cases (aPR = 1.10, 95% CI 1.02-1.20) (Table 2 ).
Discussion
An increase in post-early-stage HIV diagnosis was apparent among NC residents living near a testing site, but testing farther away than geographically necessary. The association between testing distance and infection stage was modest, with only small increases in postearly-stage diagnosis among persons traveling ≥5 miles to test but living <5 miles from another facility.
In NC, few new HIV cases tested at their closest testing facility. Among those living <5 miles from a testing site but diagnosed at a less proximate site, the increased prevalence of post-early-stage diagnoses occurred primarily among black and MSM cases, groups traditionally HIV-burdened in the South. Limited awareness of available nearby HIV services, or perceptions about diseaserelated stigma, inadequate HIV services, and confidentiality may influence people living in the South to seek HIV testing from less proximate facilities (Krawczyk et al., 2006; Leibowitz & Taylor, 2007; Reif, Geonnotti, & Whetten, 2006; Southern AIDS Coalition, 2012) .
Distance is an easy-to-derive measure, but may not fully explain geographical accessibility to HIV services. The type and efficiency of available transportation systems differ across communities (Guagliardo, 2004) , impacting the cost and time required to travel from location to location. Moreover, decisions about where to access medical services are sometimes made based on the location of friends, family or daily activities rather than residence (Eberhart, Share, Shpaner, & Brady, 2014) .
Although a substantial proportion of HIV testing in the South is conducted in health departments (Sutton, Anthony, Vila, McLellan-Lemal, & Weidle, 2010) , approximately 40% of diagnoses in NC are made at public sites. Test-seeking patterns, demographics and transmission risk behaviors among people testing at public sites may differ from those diagnosed by private providers, possibly limiting the generalizability of our results.
The use of STARHS data to assess recent HIV infection has limitations. The BED assay may misclassify late-stage disease (Bärnighausen, McWalter, Rosner, Newell, & Welte, 2010). We attempted to minimize this phenomenon by identifying and removing AIDS cases prior to assessing STARHS results. Furthermore, approximately 20% of HIV diagnoses were missing STARHS results and were excluded. These cases were more often older and black (data not shown), which may bias our results.
Distance to diagnosis site appears to have a small, yet nontrivial, impact on the prevalence of post-early-stage HIV diagnoses in NC. The approximately 120 people diagnosed during post-early stages living near a testing site, yet choosing to travel farther to test, did not have the opportunity to benefit from early care and treatment. Reasons for traveling farther and receiving a diagnosis later in the course of infection are likely varied and may cause delays in linking to HIV care and initiating treatment (Sutton et al., 2010) . Interventions increasing accessibility of HIV services (e.g., providing transportation, reducing stigma) could improve infection awareness, disease management, and transmission prevention. about the data used in this analysis. Additionally, the authors greatly appreciate the scientific support provided by Brian Pence in the design of this study.
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